ES2230679T3 - Procedimiento de preparacion de conjugados de vacunas que utilizan una sal de uronio. - Google Patents

Procedimiento de preparacion de conjugados de vacunas que utilizan una sal de uronio.

Info

Publication number
ES2230679T3
ES2230679T3 ES98910511T ES98910511T ES2230679T3 ES 2230679 T3 ES2230679 T3 ES 2230679T3 ES 98910511 T ES98910511 T ES 98910511T ES 98910511 T ES98910511 T ES 98910511T ES 2230679 T3 ES2230679 T3 ES 2230679T3
Authority
ES
Spain
Prior art keywords
radical
polysaccharide
reagent
substituted
sup
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98910511T
Other languages
English (en)
Spanish (es)
Inventor
Andrew Lees
James J. Mond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Application granted granted Critical
Publication of ES2230679T3 publication Critical patent/ES2230679T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/961—Chemistry: molecular biology and microbiology including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/964—Chemistry: molecular biology and microbiology including enzyme-ligand conjugate production, e.g. reducing rate of nonproductive linkage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES98910511T 1997-03-24 1998-03-24 Procedimiento de preparacion de conjugados de vacunas que utilizan una sal de uronio. Expired - Lifetime ES2230679T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4178197P 1997-03-24 1997-03-24
US41781P 1997-03-24

Publications (1)

Publication Number Publication Date
ES2230679T3 true ES2230679T3 (es) 2005-05-01

Family

ID=21918285

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98910511T Expired - Lifetime ES2230679T3 (es) 1997-03-24 1998-03-24 Procedimiento de preparacion de conjugados de vacunas que utilizan una sal de uronio.

Country Status (9)

Country Link
US (1) US6299881B1 (fr)
EP (1) EP0971945B1 (fr)
JP (1) JP2002501495A (fr)
AT (1) ATE278703T1 (fr)
AU (1) AU739631B2 (fr)
CA (1) CA2283762A1 (fr)
DE (1) DE69826843T2 (fr)
ES (1) ES2230679T3 (fr)
WO (1) WO1998042721A1 (fr)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1463097A (en) 1996-01-04 1997-08-01 Rican Limited Helicobacter pylori bacterioferritin
TW409058B (en) * 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
US6756493B1 (en) 1998-09-01 2004-06-29 Antex Biologics, Inc. Nucleic acid sequence and uses thereof
US6693186B2 (en) 1998-09-01 2004-02-17 Antex Biologics Inc Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
FR2803913B1 (fr) * 2000-01-13 2002-08-16 Pasteur Sanofi Diagnostics Procede d'immobilisation de reactif(s) affin(s) sur phase solide hydrophobe
DE10112825A1 (de) * 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
JP4646516B2 (ja) 2002-02-20 2011-03-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着したポリペプチド含有分子を有する微粒子
DE10209821A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
MXPA04011249A (es) 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
BR0314106A (pt) * 2002-09-11 2005-07-19 Fresenius Kabi De Gmbh Polipeptìdeos hasilados, especialmente eritropoietina hasilada
DE10242076A1 (de) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
AU2003273413A1 (en) * 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
CA2501812C (fr) 2002-10-11 2012-07-10 Mariagrazia Pizza Vaccins polypeptidiques offrant une large protection contre des lignees de meningocoques hypervirulentes
MY132859A (en) 2002-11-01 2007-10-31 Glaxosmithkline Biologicals Sa Immunogenic composition
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US8034378B2 (en) 2002-12-27 2011-10-11 Novartis Vaccines And Diagnostics, Inc Immunogenic compositions containing phospholipid
CA2514328C (fr) 2003-01-30 2020-01-14 Chiron Srl Vaccins injectables contre les multiples serogroupes du meningocoque
CA2520124A1 (fr) 2003-03-28 2004-10-14 Chiron Corporation Utilisation de composes de benzazole pour l' immunostimulation
DE602004022286D1 (de) 2003-06-02 2009-09-10 Novartis Vaccines & Diagnostic Immunogene zusammensetzungen auf basis von biologisch abbaubaren mikroteilchen enthaltend ein diphtherie- und ein tetanustoxoid
WO2005014655A2 (fr) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugues d'amidon d'hydroxyalkyle et de proteine
EP1653991A2 (fr) * 2003-08-08 2006-05-10 Fresenius Kabi Deutschland GmbH Conjugues de polymere et de proteine lies au moyen d'un groupe de liaison oxime
US20080274948A1 (en) * 2003-08-08 2008-11-06 Fresenius Kabi Deutschland Gmbh Conjugates of Hydroxyalkyl Starch and G-Csf
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CA2540896C (fr) 2003-10-02 2015-06-02 Chiron Srl Vaccins liquides contre de multiples serogroupes meningococciques
EP1713508A2 (fr) * 2004-01-29 2006-10-25 Biosynexus Incorporated Utilisation de groupes fonctionnels amino-oxy dans la preparation de vaccins
JP5191729B2 (ja) 2004-03-11 2013-05-08 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 還元的アミノ化によって製造される、ヒドロキシアルキルデンプンとタンパク質とのコンジュゲート
EP1758608A2 (fr) * 2004-03-11 2007-03-07 Fresenius Kabi Deutschland GmbH Conjugues d'hydroxy-ethyl-amidon et d'erythropoietine
ES2390885T3 (es) * 2004-03-11 2012-11-19 Fresenius Kabi Deutschland Gmbh Conjugados de hidroxialquilalmidón y una proteína
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
NZ550533A (en) 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
US20050281855A1 (en) * 2004-06-18 2005-12-22 National Defense Medical Center Process for preparing a cross-linked carboxyl polysaccharide and the cross-linked carboxyl polysaccharide
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP2277595A3 (fr) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Composés pour potentialiser l'immunité
EP1768662A2 (fr) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
WO2006078318A2 (fr) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Compositions immunogenes pour bacteries a gram positif telles que streptococcus agalactiae
US20060040410A1 (en) * 2004-08-18 2006-02-23 Fuji Photo Film Co., Ltd. Biosensor
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
JP2008532966A (ja) * 2005-03-11 2008-08-21 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 不活性出発物質からの生理活性糖タンパク質の生成
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
EP1896062B1 (fr) 2005-06-27 2010-03-31 GlaxoSmithKline Biologicals S.A. Composition immunogène
CA2621023C (fr) 2005-09-01 2019-07-02 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Vaccination multiple comprenant des meningocoques du serogroupe c
EP1762250A1 (fr) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugués d' amidon hydroxyalkyle et une substance active obtenue par ligation chimique via thiazolidine
GB0522303D0 (en) 2005-11-01 2005-12-07 Chiron Srl Culture method
EP2360175B1 (fr) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Particules de type virus (vlps) de norovirus et de sapovirus
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
NO346529B1 (no) 2005-12-22 2022-09-26 Glaxosmithkline Biologicals Sa Bruk av et immunogenpreparat for småbarn, omfattende 22F sakkaridkonjugat
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US10543265B2 (en) 2006-03-22 2020-01-28 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
EP2010537B1 (fr) 2006-03-23 2011-12-28 Novartis AG Composés d'imidazoquinoxaline utilisés en tant qu'immunomodulateurs
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
MX2009013112A (es) 2007-06-04 2010-03-01 Novartis Ag Formulacion de vacunas para meningitis.
SI2167121T1 (sl) 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
ES2561483T3 (es) 2007-09-12 2016-02-26 Glaxosmithkline Biologicals Sa Antígenos mutantes de GAS57 y anticuerpos de GAS57
EP2070950A1 (fr) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Dérivés hydroxyalkylés de l'amidon et leur procédé de préparation
EP2070951A1 (fr) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Procédé de production d'un dérivé hydroxyalkyle de l'amidon avec deux liens
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
JP5656642B2 (ja) 2007-12-21 2015-01-21 ノバルティス アーゲー ストレプトリシンｏの変異体形態
CA2777837C (fr) 2008-10-27 2017-07-11 Novartis Ag Procede de purification
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
EP2385842A1 (fr) 2009-01-12 2011-11-16 Novartis AG Antigènes à domaines cna_b dans des vaccins contre des bactéries à gram positif
US20120135037A1 (en) 2009-06-01 2012-05-31 Mizel Steven B Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
RU2603267C2 (ru) 2009-09-30 2016-11-27 Новартис Аг Конъюгация капсульных полисахаридов staphylococcus aureus типа 5 и типа 8
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
HUE034251T2 (en) 2009-10-30 2018-02-28 Glaxosmithkline Biologicals Sa Purification of type 5 and type 8 capsular saccharides from Staphylococcus aureus
BR122022002084B1 (pt) 2009-12-17 2022-08-16 Fina Biosolutions, Llc Processo de conjugação de carboidratos na preparação de vacinas conjugadas e suas respectivas vacinas
EP2519265B1 (fr) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Immunogènes de polysaccharide conjugués à des protéines porteuses de e. coli
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
WO2012020326A1 (fr) 2010-03-18 2012-02-16 Novartis Ag Vaccins adjuvantés contre le méningocoque de sérogroupe b
BR112012025364A2 (pt) 2010-04-07 2015-09-22 Novartis Ag método para geração de partícula semelhante a vírus de parvovírus b19
US8383783B2 (en) 2010-04-23 2013-02-26 Serum Institute Of India, Ltd. Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels
WO2011149564A1 (fr) 2010-05-28 2011-12-01 Tetris Online, Inc. Infrastructure de jeu informatique asynchrone hybride interactif
EP2591097A1 (fr) 2010-07-06 2013-05-15 Novartis AG Compositions immunogènes dérivées d'un norovirus et méthodes
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CA2860331A1 (fr) 2010-12-24 2012-06-28 Novartis Ag Composes
CA2828844C (fr) 2011-03-02 2020-07-14 Novartis Ag Vaccins combines comprenant des doses inferieures d'antigene et/ou d'adjuvant
GB201106225D0 (en) 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
ES2742823T3 (es) 2011-04-22 2020-02-17 Wyeth Llc Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos
WO2013009564A1 (fr) 2011-07-08 2013-01-17 Novartis Ag Procédé de ligature de la tyrosine
WO2013016460A1 (fr) 2011-07-25 2013-01-31 Novartis Ag Compositions et procédés d'évaluation de l'immunogénicité fonctionnelle de vaccins contre un parvovirus
TR201909110T4 (tr) 2011-09-14 2019-07-22 Glaxosmithkline Biologicals Sa Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler.
EP2776069A1 (fr) 2011-11-07 2014-09-17 Novartis AG Molécule porteuse comprenant un antigène spr0096 et un antigène spr2021
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
EP2592137A1 (fr) 2011-11-11 2013-05-15 Novartis AG Support de fermentation sans composants dérivés d'animaux pour la production des toxoïdes diphtériques adaptées à l'utilisation du vaccin humain
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
WO2013132043A1 (fr) 2012-03-08 2013-09-12 Novartis Ag Vaccins combinés comprenant des agonistes du tlr4
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR20150021933A (ko) 2012-05-22 2015-03-03 노파르티스 아게 수막염구균 혈청군 x 포합체
WO2013188539A2 (fr) * 2012-06-12 2013-12-19 Fina Biosolutions, Llc Fonctionnalisation différentielle des polymères avec des réactifs amino‑oxy pour des dosages diagnostiques
MX2015002717A (es) 2012-09-06 2015-05-15 Novartis Ag Vacunas combinadas con meningococo del serogrupo b y toxoides de difteria/tetanos/tosferina.
US20160101187A1 (en) 2012-10-02 2016-04-14 Novartis Ag Nonlinear saccharide conjugates
JP6266631B2 (ja) 2012-10-03 2018-01-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
SG11201502599TA (en) 2012-10-12 2015-05-28 Glaxosmithkline Biolog Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
JP2016502994A (ja) 2012-12-18 2016-02-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ジフテリア及び／又は破傷風から防御するためのコンジュゲート
JP2016501550A (ja) 2012-12-27 2016-01-21 グリコヴァキシン アーゲー Ｃｒｍ１９７に関する方法及び組成物
CN105593238B (zh) 2013-07-11 2020-09-08 诺华股份有限公司 使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰
KR102199096B1 (ko) 2013-09-08 2021-01-06 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
WO2015095868A1 (fr) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Méthodes et compositions permettant d'augmenter les taux d'anticorps protecteurs induits par des vaccins antipneumococciques polyosidiques
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
ES2820824T3 (es) 2014-01-21 2021-04-22 Pfizer Composiciones inmunogénicas que comprenden antígenos sacáridos capsulares conjugados y usos de las mismas
HRP20231504T1 (hr) 2014-01-21 2024-03-01 Pfizer Inc. Polisaharidi kapsule iz bakterije streptococcus pneumoniae i njihovi konjugati
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (fr) 2014-12-19 2016-06-22 Novartis AG Purification de polysaccharides capsulaires de streptocoques
BR112017013891B1 (pt) 2015-01-15 2024-01-30 Pfizer Inc Composições imunogênicas para uso em vacinas pneumocócicas
WO2016178123A1 (fr) 2015-05-04 2016-11-10 Pfizer Inc. Conjugués polysaccharide-protéine de streptococcus du groupe b, procédé de production de conjugués, compositions immunogènes comprenant les conjugués et leurs utilisations
TWI720448B (zh) 2015-07-21 2021-03-01 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
US10786561B2 (en) 2015-11-20 2020-09-29 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
EP3269385A1 (fr) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composition de conjugués de polysaccharide-protéine pneumococcique
WO2017220753A1 (fr) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition de conjugué polysaccharide pneumococcique-protéine
EA039427B1 (ru) 2016-08-05 2022-01-26 Санофи Пастер Инк. Поливалентная пневмококковая полисахаридно-белковая конъюгатная композиция
KR102437120B1 (ko) 2016-08-05 2022-08-25 사노피 파스퇴르 인코포레이티드 다가 폐렴구균 다당류-단백질 접합체 조성물
WO2018042015A1 (fr) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccins contre neisseria gonorrhoeae
KR102608081B1 (ko) 2016-09-30 2023-11-29 바이오로지칼 이 리미티드 폴리사카라이드-단백질 접합체를 포함하는 다가 폐렴구균 백신 조성물
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
EP3551668A1 (fr) 2016-12-06 2019-10-16 GlaxoSmithKline Biologicals S.A. Procédé de purification pour polysaccharide capsulaire
EP3570879B1 (fr) 2017-01-20 2022-03-30 Pfizer Inc. Composition immunogène pour l'utilisation dans vaccin pneumococcique
KR102650073B1 (ko) 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
EP3577130A2 (fr) 2017-01-31 2019-12-11 Pfizer Inc Compositions de neisseria meningitidis et méthodes associées
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CA3074708A1 (fr) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Polysaccharides antipneumococciques et leur utilisation dans des conjugues immunogenes polysaccharide-proteine porteuse
CA3084436A1 (fr) 2017-12-06 2019-07-18 Merck Sharp & Dohme Corp. Compositions comprenant des conjugues polysaccharide-proteine de streptococcus pneumoniae et leurs methodes d'utilisation
WO2020043874A1 (fr) 2018-08-31 2020-03-05 Glaxosmithkline Biologicals Sa Vaccin conjugué contre haemophilus influenzae utilisant une vésicule de membrane externe de bordetella
JP2022512345A (ja) 2018-12-12 2022-02-03 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
EP3897705A2 (fr) 2018-12-19 2021-10-27 Merck Sharp & Dohme Corp. Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation
WO2020165711A1 (fr) 2019-02-11 2020-08-20 Pfizer Inc. COMPOSITIONS DE NEISSERIA MENINGITIDIS<i /> ET PROCÉDÉS ASSOCIÉES
WO2020208502A1 (fr) 2019-04-10 2020-10-15 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués, kits les comprenant et leurs utilisations
MX2021013736A (es) 2019-05-10 2021-12-10 Glaxosmithkline Biologicals Sa Produccion de conjugados.
MX2022001241A (es) 2019-07-31 2022-04-20 Sanofi Pasteur Inc Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos.
KR20220069992A (ko) 2019-09-27 2022-05-27 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
EP3799884A1 (fr) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Compositions immunogènes
EP3900739A1 (fr) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Conjugués saccharides synthétiques de streptococcus pneumoniae à une protéine de membrane conservée
EP3919076A1 (fr) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccins synthétiques d'oligosaccharide contre le streptococcus pneumoniae avec des formulations d'adjuvant de microparticules
EP4164681A1 (fr) 2020-06-12 2023-04-19 GlaxoSmithKline Biologicals S.A. Immunisation bactérienne à l'aide d'un vaccin à nanoparticules
KR20230056727A (ko) 2020-08-26 2023-04-27 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
WO2022058945A1 (fr) 2020-09-17 2022-03-24 Janssen Pharmaceuticals, Inc. Compositions de vaccin multivalentes et leurs utilisations
MX2023005221A (es) 2020-11-04 2023-05-16 Pfizer Composiciones inmunogenicas para uso en vacunas neumococicas.
CA3201450A1 (fr) 2020-11-13 2022-05-19 Glaxosmithkline Biologicals Sa Transporteurs de proteine bacterienne et procedes de conjugaison
WO2023111826A1 (fr) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Immunisation bactérienne utilisant des constructions de nanoparticules en épingle à cheveux qbêta
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (fr) 2022-12-01 2024-06-06 Pfizer Inc. Formulations de vaccin pneumococcique conjugué

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4122094A (en) * 1976-06-09 1978-10-24 Lever Brothers Company Separation of the isomers of tocopherol by liquid/solid chromatography
US5585264A (en) * 1988-07-15 1996-12-17 University Of Saskatchewan Nucleotide sequences encoding recombinant bovine herpesvirus type-1 GI, GIII and GIV polypeptides
DE4016596A1 (de) 1990-05-23 1991-11-28 Hoechst Ag Ein neues kupplungsreagenz fuer die peptidsynthese
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5843463A (en) * 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
US5304497A (en) * 1991-10-15 1994-04-19 Applied Biosystems, Inc. Method of forming N-protected amino acid thiohydantoins
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
EP0911036A3 (fr) * 1992-02-11 2001-05-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Structure immunogene à double vecteur
EP0636186B1 (fr) * 1992-04-03 1998-11-25 The Perkin-Elmer Corporation Procede et composition de sondage
JPH0649100A (ja) * 1992-05-06 1994-02-22 Eastman Kodak Co カルボキシル化基体への化合物の結合方法
EP0662078B1 (fr) * 1992-09-28 2003-05-02 Research Corporation Technologies, Inc. Reactifs destines aux couplages peptidiques
NZ274376A (en) * 1993-09-22 1997-11-24 Jackson H M Found Military Med Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs
US5539083A (en) * 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
DE4427980A1 (de) * 1994-08-08 1996-02-15 Bayer Ag Nukleinsäuren-bindende Oligomere für Therapie und Diagnostik
EP0814833B1 (fr) 1995-03-22 2003-05-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine Preparation de produits de recombinaison immunogenes au moyen d'hydrates de carbone solubles actives par l'intermediaire de reactifs organiques de cyanylation
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines

Also Published As

Publication number Publication date
US6299881B1 (en) 2001-10-09
AU6473798A (en) 1998-10-20
DE69826843D1 (de) 2004-11-11
EP0971945B1 (fr) 2004-10-06
WO1998042721A1 (fr) 1998-10-01
ATE278703T1 (de) 2004-10-15
DE69826843T2 (de) 2005-02-10
CA2283762A1 (fr) 1998-10-01
EP0971945A1 (fr) 2000-01-19
JP2002501495A (ja) 2002-01-15
AU739631B2 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
ES2230679T3 (es) Procedimiento de preparacion de conjugados de vacunas que utilizan una sal de uronio.
AU678613B2 (en) Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
EP0625910B1 (fr) Structure immunogene a double vecteur
EP0186576B1 (fr) Polysaccharides bactériens neutres modifiés de manière covalente, conjugés stables covalents entre ces polysaccharides et des protéines immunogéniques et méthodes de préparation de ces polysaccharides et conjugués
AU728026B2 (en) Preparation of protein-polysaccharide conjugate vaccines using homobifunctional and heterobifunctional vinylsulfones
ES2230687T3 (es) Copulacion de proteinas nomodificadas con polisacaridos derivados de haloacilo o de dihaloacilo para la preparacion de vacunas que incluyen proteinas-polisacaridos.
Peeters et al. Preparation of polysaccharide-conjugate vaccines
US6165468A (en) Antigenic carbohydrate linked to an immunogenic carrier
Peeters et al. Polysaccharicb-conjugate vaccines
KR19980703201A (ko) 유기 시아닐화제로 활성화된 가용성 탄수화물을 이용한 면역원성 구조체 제조